Alvotech

ALVO • Drug Manufacturers - Specialty & Generic

$5.32

▼ -0.06 (-1.12%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL EQUILIBRADONeutralConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil mixto. La empresa no es necesariamente mala, pero la valoración, el crecimiento o el balance todavía no justifican una señal más fuerte.

Capitalización

$1.90B

Crecimiento

58.8%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Crecimiento positivo de ingresos · 15.6%Liquidez saludable · 1.89Múltiplo de ganancias caro · 51.3

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 21 ago 2026, 12:09 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$5.32

Change-1.12%

Shares Out356.82M

Market Cap$1.90B

Enterprise Value$3.07B

52W Range2.94 - 9.25

Beta0.18

P/E-10.57

P/S3.86

P/B-9.91

P/FCF-6.28

EV/Sales6.25

Price$5.32

Change-1.12%

Shares Out356.82M

Market Cap$1.90B

Enterprise Value$3.07B

52W Range2.94 - 9.25

Beta0.18

P/E-10.57

P/S3.86

P/B-9.91

P/FCF-6.28

EV/Sales6.25

EV/EBITDA-33.27

EV/FCF-10.16

Earnings Yield-9.46%

FCF Yield-15.93%

Dividend Yield0.00%

Gross Margin59.82%

Oper. Margin13.34%

Profit Margin4.76%

Debt/Eq-5.09

Current Ratio1.89

Quick Ratio1.16

Revenue 5Y58.79%

Target$8.60

Target Upside61.65%

Target Median$10.00

Target Range5.00 - 10.00

Volume1.37M

Avg Volume731.81K

EPS Surprise-0.02

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

58/100

Fortaleza financiera

Deuda, caja, estabilidad

63/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

64/100

Por qué este puntaje▼

Crecimiento positivo de ingresos · 15.6%Liquidez saludable · 1.89Múltiplo de ganancias caro · 51.3

Analyst view

Analyst sentiment and price target

ALVO

Analyst sentiment

Based on 5 analyst votes · 2026-09-05

60/100

Neutral

Bullish

Hold

Bearish

Precio objetivo

2026-08-21

Bajo

$5.00

Promedio

$8.60

Mediana

$10.00

Alto

$10.00

Resumen de la compañía

IPO: 6/16/2022

Industria: Drug Manufacturers - Specialty & Generic

P/B i: -9.91

Deuda / Patrimonio i: -5.09

Margen operativo: 13.34%

Margen neto: 4.76%

ROE i: -

ROIC: -

Salud financiera

Puntaje13 / 20

Deuda / Patrimonio: -5.09

Ratio corriente: 1.89

Ratio rápido: 1.16

Estado: Good

🧾

No hay actividad interna

No hay transacciones internas recientes disponibles.

Sobre la compañía

Alvotech

Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.

Fuente - Link

Competidores

AMPH BHVN COLL EVO HROW PAHC PGNY SEM TLRY UFPT

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations

REYKJAVIK, Iceland, August 31, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT80, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) prefilled syringe and autoinjector for subcutaneous administration.

GlobeNewsWire

Alvotech to present at upcoming investor conferences in September

REYKJAVIK, ICELAND (August 27, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Robert Wessman, Founder and Chairman, and Dr. Balaji V. Prasad, Chief Strategy Officer, will participate in the upcoming investor conferences in September as follows:

GlobeNewsWire

Napco Security Technologies Posts Upbeat Q4 Results, Joins Alvotech, Rum Group And Other Big Stocks Moving Higher On Monday

U.S. stocks were mixed, with the Dow Jones index gaining around 150 points on Monday.

Benzinga

Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets

REYKJAVIK, Iceland, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical (TWSE Stock Code: 1795) covering two of Alvotech's candidates in the United States and selected Asian markets: AVT34, a proposed biosimilar to Imfinzi® (durvalumab), and AVT87, a proposed biosimilar to Hemlibra® (emicizumab).

GlobeNewsWire

Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts

Alvotech maintains at a Hold rating due to missed H1 2026 earnings and ongoing regulatory challenges, despite pipeline progress. Recent FDA CRLs for AVT05 and AVT06 were due to manufacturing issues, now addressed, with BLAs resubmitted and multiple approvals targeted for Q4 2026. AVT06, a biosimilar to EYLEA, has global commercialization rights secured post-November 2026, with patent disputes resolved and a large market opportunity.

Seeking Alpha

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-06	-0.07	-0.09	-0.02
2026-03-18	-0.00575	-0.37	-0.36425
2025-11-12	0.05	-0.02	-0.07
2025-08-13	-0.26	0.14	0.4
2025-05-07	-0.17	0.35	0.52
2025-03-26	-0.39	-0.24	0.15
2024-11-13	-0.063	0.19	0.253
2024-08-15	-0.28	0.28	0.56
2024-05-21	-0.083	-0.89	-0.807
2024-03-20	0.15	-1.22	-1.37
2023-11-28	-0.29	-0.82	-0.53
2023-08-30	-0.14	-0.43	-0.29